Cargando…
Pharmacometabolomics study identifies circulating spermidine and tryptophan as potential biomarkers associated with the complete pathological response to trastuzumab-paclitaxel neoadjuvant therapy in HER-2 positive breast cancer
Defining biomarkers that predict therapeutic effects and adverse events is a crucial mandate to guide patient selection for personalized cancer treatments. In the present study, we applied a pharmacometabolomics approach to identify biomarkers potentially associated with pathological complete respon...
Autores principales: | Miolo, Gianmaria, Muraro, Elena, Caruso, Donatella, Crivellari, Diana, Ash, Anthony, Scalone, Simona, Lombardi, Davide, Rizzolio, Flavio, Giordano, Antonio, Corona, Giuseppe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5129972/ https://www.ncbi.nlm.nih.gov/pubmed/27223427 http://dx.doi.org/10.18632/oncotarget.9489 |
Ejemplares similares
-
Pharmacometabolomics of trabectedin in metastatic soft tissue sarcoma patients
por: Corona, Giuseppe, et al.
Publicado: (2023) -
Anthracycline-free neoadjuvant therapy induces pathological complete responses by exploiting immune proficiency in HER2+ breast cancer patients
por: Miolo, Gianmaria, et al.
Publicado: (2014) -
KIR-HLA Functional Repertoire Influences Trastuzumab Efficiency in Patients With HER2-Positive Breast Cancer
por: Muraro, Elena, et al.
Publicado: (2022) -
Late tamoxifen in patients previously operated for breast cancer without postoperative tamoxifen: 5-year results of a single institution randomised study
por: Veronesi, Andrea, et al.
Publicado: (2010) -
Improved Natural Killer cell activity and retained anti-tumor CD8(+) T cell responses contribute to the induction of a pathological complete response in HER2-positive breast cancer patients undergoing neoadjuvant chemotherapy
por: Muraro, E, et al.
Publicado: (2015)